| Literature DB >> 30489209 |
Yong-Yao Wu1,2, Xiao-Hui Qiu2, Yun Ye1, Chao Gao3, Fuquan Wu1, Guihua Xia1.
Abstract
OBJECTIVE: Uric acid (UA) is a risk marker of CKD and SUA level in CKD 3-4 patients closely correlates with hyperuricemic nephropathy (HN) morbidity. This study was designed to evaluate the risk factors for HN in CKD 3-4 patients.Entities:
Keywords: CKD 3–4; hUAT; hyperuricemia; hyperuricemic nephropathy; serum uric acid
Mesh:
Substances:
Year: 2018 PMID: 30489209 PMCID: PMC6282434 DOI: 10.1080/0886022X.2018.1487859
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
The clinical and biochemical characteristics of CKD patients in this study and the differences among groups.
| Parameters | Groups | |||
|---|---|---|---|---|
| Normal type | Underexeret type | Overproduct type | ||
| Patients ( | 193 (41.87%) | 164 (35.57%) | 104 (22.56%) | <.0001 |
| Age (years) | 45.9 ± 7.3 | 48.1 ± 10.0 | 56.9 ± 9.2 | <.0001 |
| BMI | 23.1 ± 3.3 | 24.1 ± 4.2 | 25.6 ± 3.4 | =.0284 |
| WHR | 0.9 ± 0.3 | 1.0 ± 0.4 | 1.1 ± 0.3 | =.0320 |
| Roasted fish consumption (g/d) | 11.9 ± 6.6 | 18.3 ± 6.8 | 35.9 ± 11.9 | <.0001 |
| Alcohol consumption (mL/d) | 20.6 ± 7.1 | 33.5 ± 10.5 | 42.9 ± 13.9 | <.0001 |
| Smoking (times/d, mean) | 8.8 ± 5.3 | 12.4 ± 5.7 | 16.8 ± 10.4 | =.0763 |
| Water consumption (L/d) | 1.4 ± 0.7 | 1.1 ± 0.4 | 0.9 ± 0.4 | =.0219 |
| Primary SUA (μmol/L) | 353.9 ± 68.1 | 387.8 ± 62.4 | 398.8 ± 63.4 | =.0274 |
| Primary UUA (mmol/L) | 4.0 ± 0.6 | 4.3 ± 0.7 | 4.7 ± 0.8 | =.2976 |
| HN (%, | 68.4% (132/193) | 87.6% (147/164) | 88.6% (92/104) | <.0001 |
| p.5 d SUA (μmol/L) | 290.6 ± 67.7 | 315.1 ± 61.8 | 350.5 ± 57.9 | =.0071 |
| p.5 d UUA (mmol/L) | 1.9 ± 0.4 | 3.2 ± 0.3 | 4.5 ± 0.8 | <.0001 |
| TG/HDL ratio | 3.1 ± 1.1 | 3.4 ± 0.9 | 3.9 ± 0.5 | =.0027 |
| CHO (mg/dL) | 4.7 ± 0.8 | 4.9 ± 1.0 | 5.3 ± 1.4 | =.0827 |
| SBP (mmHg) | 134.8 ± 13.2 | 140.7 ± 11.0 | 158.7 ± 15.0 | <.0001 |
| DBP (mmHg) | 95.1 ± 7.2 | 99.9 ± 8.8 | 101.5 ± 6.9 | =.0165 |
| uNgal/Cr. ratio (ng/mL Cr.) | 4.5 ± 0.8 | 5.1 ± 2.2 | 7.3 ± 2.3 | <.0001 |
| uKim-1/Cr. ratio (ng/mL, Cr.) | 1.5 ± 0.8 | 3.6 ± 0.9 | 7.3 ± 2.3 | <.0001 |
| eGFR (mL/min/1.73 m2) | 109.6 ± 19.6 | 102.5 ± 23.9 | 98.1 ± 10.6 | =.0125 |
| XOD (U/L) | 3.5 ± 2.6 | 4.7 ± 4.1 | 8.8 ± 3.7 | <.0001 |
| CRP (mg/L) | 26.8 ± 4.1 | 33.4 ± 7.8 | 40.4 ± 7.9 | <.0001 |
From up to down: BMI: body mass index; WHR: waist hip ratio; SUA: serum uric acid; UUA: urine uric acid; HUA: hyperuricemia; TG: triglycerides; HDL: high-density lipoprotein; HN: hyperuricemic nephropathy; CHO: cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; uNGAL: urine neutrophil gelatinase-associated lipocalin; uKim-1: urine kidney molecule-1; Cr: creatinine; eGFR: estimated glomerular filtration rate; XOD: xanthine oxidase; CRP: C-reactive protein. p(0).5 d: indicates post five days.
Multiple linear regression analysis of the URAT1 mRNA relative expression level.
| Variables | Coefficient | OR (95% CI) | |
|---|---|---|---|
| SUA (μmol/L) | 1.125 | 3.435 (1.762−5.493) | <.001 |
| CHO (mg/dL) | 0.522 | 1.673 (1.079−2.681) | .012 |
| SBP (mmHg) | 0.518 | 1.520 (1.127−2.798) | .011 |
| uNgal/Cr. ratio (ng/mL Cr.) | 0.335 | 1.803 (1.592−2.985) | .030 |
From up to down: SUA: serum uric acid; CHO: cholesterol; SBP: systolic blood pressure; uNGAL: urine neutrophil gelatinase-associated lipocalin; Cr.: creatinine.
Figure 1.Correlation analysis for hUAT and hURAT1 mRNA relative expression levels with SUA concentrations in underexeret CKD patients.